Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1071 • ACR Convergence 2023
No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs)
Madeline O'Sullivan¹, Grant Cannon¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel⁴, Jessica A Walsh⁵, Punyasha Roul⁶, Bryant England⁶, Ted R Mikuls⁷, Joshua Baker⁸ and Tawnie Braaten⁴, ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴University of Utah, Salt Lake City, UT, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Immune checkpoint inhibitors (ICIs) are used to treat multiple cancers with increasing frequency and have led to improved survival. However, there is limited data…
Abstract Number: 1272 • ACR Convergence 2023
Immunomodulators and Risk for Breakthrough COVID-19 After a Third SARS-CoV-2 mRNA Vaccine Among Patients with Rheumatoid Arthritis: A Cohort Study
Abigail Schiff¹, Xiaosong Wang¹, Naomi Patel², Yumeko Kawano¹, Jennifer Hanberg³, Emily Kowalski¹, Claire Cook², Kathleen Vanni¹, Grace Qian¹, Katarina Bade⁴, Alene Saavedra¹, Shruthi Srivatsan², Zachary Williams², Rathnam Venkat¹, Zachary Wallace⁵ and Jeffrey Sparks⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA, ⁶Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: In August 2021, the CDC recommended a third SARS-CoV-2 mRNA vaccine dose to complete the initial vaccine series for immunosuppressed patients who had previously…
Abstract Number: 1288 • ACR Convergence 2023
Frailty Is Associated with Higher Risk of Readmission in Patients with Rheumatoid Arthritis
Waqas Tahir¹, Yenny Rosli², Christopher Leung³, K Wysham⁴, Jiha Lee⁵, Radjiv Goulabchand⁶, Una Makris⁷, Siddharth Singh⁸ and Namrata Singh⁹, ¹Mayo Clinic, Jacksonville, FL, ²University of Washington, Seattle, WA, ³Georgetown University School of Medicine, Washington, DC, ⁴VA Puget Sound/University of Washington, Seattle, WA, ⁵University of Michigan, Ann Arbor, MI, ⁶University of California San Diego, La Jolla, CA, ⁷UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁸University of California San Diego, San Diego, CA, ⁹University of Washington, Bellevue, WA
Background/Purpose: With the advent of new therapies and increasing life expectancy, there is a rising number of older adults living with rheumatoid arthritis (RA). Patients…
Abstract Number: 1304 • ACR Convergence 2023
Window of Opportunity to Achieve Better Functional Outcomes in Patients with RA: Effectiveness of an Early Treatment Strategy
Vivian Bykerk¹, Isabel Castrejon², Vibeke Strand³, Stephanie Dahan⁴, Raul Castellanos-Moreira⁵, Leo Chen⁶ and Wayne Little⁴, ¹Department of Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital Universitario Gregorio Marañón, Madrid, Spain, ³Stanford University, Palo Alto, CA, ⁴Bristol Myers Squibb, Princeton, NJ, ⁵Bristol Myers Squibb, Madrid, Spain, ⁶Syneos Health, Vancouver, BC, Canada
Background/Purpose: RA is a chronic disease that can lead to irreversible damage and functional decline with delayed or inadequate treatment.1 Abatacept + MTX is effective…
Abstract Number: 1320 • ACR Convergence 2023
Evaluation of Circulating Levels of Helper T and Innate Lymphoid Cells Subsets in a Cohort of bDMARDs-naïve Patients with Rheumatoid Arthritis Treated with Abatacept
Paolo Semeraro¹, Fabrizio Angeli¹, Alessia Caproli¹, Franco Franceschini², Paolo Airò³ and Silvia Piantoni⁴, ¹Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ⁴ASST Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Helper T cells (Th) are key players in rheumatoid arthritis (RA). Th17 and Th17.1 have a prominent function in the early phase of inflammation,…
Abstract Number: 1337 • ACR Convergence 2023
Effect of Tofacitinib Therapy on Angiotensin Converting Enzyme Activity in Rheumatoid Arthritis
Dorottya Kacsándi, Miklós Fagyas, Ágnes Horváth, Edit Végh, Anita Pusztai, Monika Czókolyová, Boglárka Soós, Attila Ádám Szabó, Attila Hamar, Zsófia Pethő, Nóra Bodnár, György Kerekes, Katalin Hodosi, Szilvia Szamosi, Gabriella Szücs, Zoltán Papp and Zoltán Szekanecz, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: The Renin-Angiotensin-Aldosterone system (RAAS) has been implicated in the regulation of the cardiovascular system and linked to rheumatoid arthritis (RA). Little information has become…
Abstract Number: 1583 • ACR Convergence 2023
Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)
Chandra Bhushan Prasad¹, Varun Dhir², Ranjan Gupta³, Koshy Nithin Thomas⁴, Devarasetti phani kumar⁵, VENKATESH S PAI⁶, Avinash Jain⁷, Shankar Naidu⁸, Priya Saini⁸, Leishangthem Bidyalaxmi⁸, AASTHA KHULLAR⁸, Ramesh Manthri⁹, Shefali Sharma¹⁰, Aman Sharma¹¹, Amita Aggarwal⁴ and Sanjay Jain⁸, ¹Healthway Hospital, Goa, Zuarinagar, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³All India Institute of Medical Sciences, New Delhi, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁵Nizams Institute of Medical Sciences, Hyderabad, India, ⁶AIIMS RISHIKESH, Rishikesh, India, ⁷SMS Medical College, Lucknow, India, ⁸PGIMER, Chandigarh, India, ⁹Department of Clinical Immunology and Rheumatology, Nizams Institute of Medical Sciences, Hyderabad, India, ¹⁰PGIMER< Chandigarh, Chandigarh, India, ¹¹PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: Methotrexate (MTX), the anchor drug for rheumatoid arthritis (RA), has limited bioavailability above an oral dose of 15 mg. Split-dose oral MTX (morning, evening…
Abstract Number: 1719 • ACR Convergence 2023
Exploring the Link Between Osteitis and Bone Microstructure Changes in Rheumatoid Arthritis: Role of JAK-STAT Signaling Pathway
Tsuneyasu Yoshida¹, Yoichi Nakayama¹, Masao Katsushima², Yuri Nishida³, Mirei Shirakashi¹, Ran Nakashima¹, Ryu Watanabe², Kosaku Murakami⁴, Hajime Yoshifuji¹, Akio Morinobu¹ and Motomu Hashimoto², ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan, ³Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan, ⁴Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Osteitis on MRI and bone microstructure changes (BMC) on high-resolution peripheral quantitative CT are the earliest signs of arthritis, preceding the development of bone…
Abstract Number: 1739 • ACR Convergence 2023
Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies
Khetam Ghannam¹, Marieluise Kirchner², Holger Bang³, Thomas Häupl⁴, Sarah Ohrndorf¹, Jan Zernicke¹, Ulrike Kuckelkorn⁵, Philipp Mertins⁶, Eugen Feist⁷ and Gerd Burmester⁸, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, ³Orgentec Diagnostika GmbH, Mainz, Germany, ⁴Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ⁵Institute of Biochemistry, Berlin, Germany, ⁶Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, ⁷Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ⁸Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease characterized by synovial inflammation and progressive joint destruction. Given the presumed pathophysiologic role of…
Abstract Number: 1755 • ACR Convergence 2023
Unique Pattern of Cadherin 6 Localization in Fibroblast-Like Synoviocytes
Camilla R. L. Machado¹, David Boyle¹, Narayanan B. Perumal², Robert J. Benschop³ and Gary Firestein¹, ¹University of California San Diego, San Diego, CA, ²Eli Lilly and Company, San Diego, CA, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The synovial lining of rheumatoid arthritis (RA) is formed by a network of fibroblast-like synoviocytes (FLS). Cadherins are type I transmembrane proteins and participate…
Abstract Number: 1771 • ACR Convergence 2023
Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Verónica Pulito-Cueto¹, David Iturbe-Fernández², Victor Mora-Cuesta², Joao Carlos Batista-Liz¹, Belén Atienza-Mateo³, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Miguel A Gonzalez-Gay⁴, Jose Cifrian⁵, Ricardo Blanco¹ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁵Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain
Background/Purpose: Periostin is an extracellular matrix protein that contributes to the development and repair of lung tissue [1]. Previous works have described periostin as a…
Abstract Number: 1885 • ACR Convergence 2023
The Frequency and Importance of Subchondral Radius Cysts in Rheumatoid Arthritis Patients Under B/tsDMARDs
Umut Kalyoncu¹ and Gizem Ayan², ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Hacettepe University Faculty of Medicine Division of Rheumatology, Ankara, Turkey
Background/Purpose: The presence of subchondral cysts in patients with rheumatoid arthritis (RA) has long been recognised. The concept of geodes used in geology would be…
Abstract Number: 2033 • ACR Convergence 2023
Sex Differences in Patient-Reported Outcomes in Patients with Rheumatoid Arthritis After Starting a New Disease-Modifying Antirheumatic Medication
John Davis¹, Sara Achenbach², Courtney Arment¹, Delamo Bekele¹, Vanessa Kronzer¹, Thomas Mason¹, Elena Myasoedova¹, Lynne Peterson¹, Kerry Wright¹ and Cynthia Crowson¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Patient-Reported Outcome Measurement Information System (PROMIS®) measures are valued in the assessment of health outcomes for patients with rheumatoid arthritis (RA). However, little is…
Abstract Number: 2109 • ACR Convergence 2023
Real-world Positivity of 14-3-3η Protein in Rheumatoid Arthritis
Roshan Subedi¹, Massiel Jimenez Artiles², Adnan Al Najada², Afrah Misbah², Qi Wang³, Alexander Kusnik², Zhiting Tang², Syed Mohammed Faizaan Zabiullah² and Anthony Ocon⁴, ¹Rochester Regional Health/Unity Hospital, Greece, NY, ²Rochester Regional Health, Rochester, NY, ³Rochester Regional Health/Unity Hospital, Rochester, NY, ⁴Rochester Regional Health, Fairport, NY
Background/Purpose: 14-3-3η protein may be elevated in the blood of inflammatory arthritis patients. It is a commercially available novel biomarker used to aid in the…
Abstract Number: 2125 • ACR Convergence 2023
Comparing the ITIS Diet and the Mediterranean Diet in Rheumatoid Arthritis: Preliminary Findings on Clinical and Microbiome Outcomes
Marta Sala Climent¹, Martha Cedeno¹, Roxana Coras², Tiffany Holt¹, Soo-In Choi³, Abha Singh⁴, Katherine Nguyen Nguyen⁵, Susan Lee¹, Simone Zuffa Zuffa¹, Meritxell Agustin-Perez¹, Marta Fernandez-Bustamante¹, Shahrokh Golshan¹, Arthur Kavanaugh⁶ and Monica Guma⁵, ¹University of California San Diego, San Diego, CA, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³University of California San Diego, Alicante, CA, ⁴Department of Medicine, University of California San Diego, La Jolla, CA, ⁵University of California San Diego, La Jolla, CA, ⁶University of California San Diego, School of Medicine, Riverside, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic condition characterized by persistent joint inflammation, functional impairment, and disability. Adhering to a Western diet has been associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].